In the afternoon of January 9, 2018, the Deputy Director of the Construction and Management Office of Wuhan National Bio-industry Base, Mr. Qian Deping, visited our Institute. Director Qian was concerned about the difficulties in the development of the Institute after its founding in Wuhan and the problems that need to be coordinated by competent authorities. He said that they would strongly support and assist in promoting the development of our Institute.

In recent years, the policy on somatic cell therapy has been frequently modified .Since the end of year 2016, the State Food and Drug Administration has placed somatic cell therapy within the scope of drug approval. Especially in the past six months, relevant policies have been issued one after another, and the national authorities have simplified approval processes to accelerate approval and to promote the development of the bio-industry. Governments at all levels and relevant departments provide innovate ideas,  policies, and follow-ups to effectively solve problems for cell therapy enterprises, helping to boost enterprises development.